Arsenic trioxide as first-line treatment for acute promyelocytic leukemia
- 1 November 2009
- journal article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 66 (21), 1913-1918
- https://doi.org/10.2146/ajhp080342
Abstract
Purpose. The history, clinical pharmacology and toxicities, and role of arsenic trioxide as a first-line agent for treating acute promyelocytic leukemia (APL) are described.Keywords
This publication has 13 references indexed in Scilit:
- Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemiaPublished by American Society of Hematology ,2006
- Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapyAnnals of Oncology, 2005
- Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic MalignanciesJournal of Clinical Oncology, 2005
- All-trans retinoic acid/As 2 O 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemiaProceedings of the National Academy of Sciences of the United States of America, 2004
- Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemiaCancer, 2003
- Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: A single center experienceAmerican Journal of Hematology, 2002
- Acute promyelocytic leukemia: evolving therapeutic strategiesBlood, 2002
- Arsenic Trioxide Therapy for Relapsed Acute Promyelocytic Leukemia: an Useful Salvage TherapyLeukemia & Lymphoma, 2000
- Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic TrioxideThe New England Journal of Medicine, 1998
- All- trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York studyCancer Chemotherapy and Pharmacology, 1997